Thiazolidinedione safety

被引：182

作者：

Kung, Jacqueline ^{[1
]}

Henry, Robert R. ^{[2
,3
]}

机构：

[1] Tufts Univ, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA

[2] Univ Calif San Diego, Div Endocrinol & Metab, San Diego, CA 92103 USA

[3] VA San Diego Healthcare Syst, San Diego, CA USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2012年 / 11卷 / 04期

关键词：

peroxisome proliferator-activated receptor (PPAR) gamma agonists; pioglitazone; rosiglitazone; thiazolidinediones; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; ADVERSE CARDIOVASCULAR EVENTS; ACUTE MYOCARDIAL-INFARCTION; RECEPTOR-GAMMA AGONISTS; CORONARY-HEART-DISEASE; GLYCEMIC CONTROL; DOUBLE-BLIND; PPAR-GAMMA; ANTIDIABETIC AGENTS;

D O I：

10.1517/14740338.2012.691963

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed. Areas covered: This review provides a comprehensive overview of the literature from 2000 onward reporting the known side effects of rosiglitazone and pioglitazone, with commentary on the quality of the data available, putative mechanism of each side effect and clinical significance. Finally, a perspective on the future of the TZDs as a class is provided. Expert opinion: The current TZDs are first-generation, non-specific activators of peroxisome proliferator-activated receptor (PPAR) gamma, resulting in a wide array of deleterious side effects that currently limit their use. However, the development of highly targeted selective PPAR gamma modulators (SPPAR gamma Ms) and dual PPAR gamma/alpha agonists is on the horizon.

引用

页码：565 / 579

页数：15

共 100 条

[41] Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].

Gerstein, H. C. ;

Yusuf, S. ;

Holman, R. R. ;

Bosch, J. ;

Anand, S. ;

Avezum, A. ;

Budaj, A. ;

Chiasson, J. ;

Conget, I. ;

Dagenais, G. ;

Davis, M. ;

Diaz, R. ;

Dinccag, N. ;

Enjalbert, M. ;

Escalante, A. ;

Fodor, G. ;

Hanefeld, M. ;

Hedner, T. ;

Jolly, K. ;

Keltai, M. ;

Laakso, M. ;

Lanas, F. ;

Lonn, E. ;

McQueen, M. ;

Mohan, V. ;

Phillips, A. ;

Piegas, L. ;

Pirags, V. ;

Probstfield, J. ;

Shaw, J. ;

Schmid, I. ;

Teo, K. ;

Zimmet, P. ;

Zinman, B. ;

Gerstein, H. C. ;

Yusuf, S. ;

Bosch, J. ;

Pogue, J. ;

Sheridan, P. ;

Dinccag, N. ;

Hanefeld, M. ;

Hoogwerf, B. ;

Laakso, M. ;

Mohan, V. ;

Shaw, J. ;

Zinman, B. ;

Holman, R. R. ;

Diaz, R. ;

Ahuad Guerrero, R. ;

Albisu, J. .

LANCET, 2006, 368 (9541) :1096-1105

[42]

Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743

[43]

Gimble JM, 1996, MOL PHARMACOL, V50, P1087

[44] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia [J].

Goldberg, RB ;

Kendall, DM ;

Deeg, MA ;

Buse, JB ;

Zagar, AJ ;

Pinaire, JA ;

Tan, MH ;

Khan, MA ;

Perez, AT ;

Jacober, SJ .

DIABETES CARE, 2005, 28 (07) :1547-1554

[45] Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone [J].

Graham, David J. ;

Ouellet-Hellstrom, Rita ;

MaCurdy, Thomas E. ;

Ali, Farzana ;

Sholley, Christopher ;

Worrall, Christopher ;

Kelman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (04) :411-418

[46] Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption [J].

Guan, YF ;

Hao, CM ;

Cha, DR ;

Rao, R ;

Lu, WD ;

Kohan, DE ;

Magnuson, MA ;

Redha, R ;

Zhang, YH ;

Breyer, MD .

NATURE MEDICINE, 2005, 11 (08) :861-866

[47] Clinical evaluation of pioglitazone in patients with type 2 diabetes using α-glucosidase inhibitor and examination of its efficacy profile [J].

Hayashi, Y ;

Miyachi, N ;

Takeuchi, T ;

Takeuchi, Y ;

Kamiya, F ;

Kato, T ;

Imaeda, K ;

Okayama, N ;

Shimizu, M ;

Itoh, M .

DIABETES OBESITY & METABOLISM, 2003, 5 (01) :58-65

[48] Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study [J].

Henry, Robert R. ;

Lincoff, A. Michael ;

Mudaliar, Sunder ;

Rabbia, Minchael ;

Chognot, Cathy ;

Herz, Matthias .

LANCET, 2009, 374 (9684) :126-135

[49] A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus [J].

Herz, M ;

Johns, D ;

Reviriego, J ;

Grossman, LD ;

Godin, C ;

Duran, S ;

Hawkins, F ;

Lochnan, H ;

Escobar-Jiménez, F ;

Hardin, PA ;

Konkoy, CS ;

Tan, MH .

CLINICAL THERAPEUTICS, 2003, 25 (04) :1074-1095

[50] Effects of high dose aleglitazar on renal function in patients with type 2 diabetes [J].

Herz, Matthias ;

Gaspari, Flavio ;

Perico, Norberto ;

Viberti, Giancarlo ;

Urbanowska, Teresa ;

Rabbia, Michael ;

Kirk, Dominika Wieczorek .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (02) :136-142

← 1 2 3 4 5 6 7 8 9 10 →